{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T08:27:23Z","timestamp":1759480043870,"version":"3.37.3"},"reference-count":5,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2020,6,15]],"date-time":"2020-06-15T00:00:00Z","timestamp":1592179200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,4,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Emerging cancer drugs introduce new forms of nephrotoxicity that may also present as electrolyte disorders. Here, we report a patient with non-Hodgkin lymphoma who developed severe hypokalaemia with concurrent hypophosphataemia, hypocalcaemia and hypomagnesaemia secondary to venetoclax. Although electrolyte disorders have been reported during treatment with venetoclax, these were ascribed to tumour lysis prophylaxis. Based on the temporal relationship and urinary studies, we show that venetoclax can cause these electrolyte disorders, likely through an effect on the proximal and distal convoluted tubule. In patients treated with venetoclax, we recommend close monitoring of electrolytes and avoiding co-medication that can contribute to electrolyte disorders.<\/jats:p>","DOI":"10.1093\/ckj\/sfaa091","type":"journal-article","created":{"date-parts":[[2020,4,28]],"date-time":"2020-04-28T19:16:28Z","timestamp":1588101388000},"page":"1272-1274","source":"Crossref","is-referenced-by-count":4,"title":["Electrolyte disorders secondary to venetoclax"],"prefix":"10.1093","volume":"14","author":[{"given":"Nils","family":"van der Lubbe","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Erasmus Medical Center, University Medical Center Rotterdam, Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pieternella J","family":"Lugtenburg","sequence":"additional","affiliation":[{"name":"Department of Hematology, Erasmus Medical Center, University Medical Center Rotterdam, Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8738-3571","authenticated-orcid":false,"given":"Ewout J","family":"Hoorn","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Erasmus Medical Center, University Medical Center Rotterdam, Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,6,15]]},"reference":[{"key":"2021060310394336100_sfaa091-B1","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat Med"},{"key":"2021060310394336100_sfaa091-B2","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and biological correlates of response in a Phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Cancer Discov"},{"key":"2021060310394336100_sfaa091-B3","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1182\/blood-2018-11-880526","article-title":"Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial","volume":"133","author":"Zelenetz","year":"2019","journal-title":"Blood"},{"key":"2021060310394336100_sfaa091-B4","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"2021060310394336100_sfaa091-B5","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/0092-8674(93)80065-M","article-title":"Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair","volume":"75","author":"Veis","year":"1993","journal-title":"Cell"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ckj\/article-pdf\/14\/4\/1272\/38462533\/sfaa091.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ckj\/article-pdf\/14\/4\/1272\/38462533\/sfaa091.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T10:40:52Z","timestamp":1622716852000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/14\/4\/1272\/5857811"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,15]]},"references-count":5,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,6,15]]},"published-print":{"date-parts":[[2021,4,2]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfaa091","relation":{},"ISSN":["2048-8513"],"issn-type":[{"type":"electronic","value":"2048-8513"}],"subject":[],"published-other":{"date-parts":[[2021,4,1]]},"published":{"date-parts":[[2020,6,15]]}}}